Pharmaceutical manufacturers in Pakistan are warning the Pakistan Government that shortages in life-saving drugs are a result of the ongoing dispute over drug prices.
Pricing dispute causing drug shortages in Pakistan
Home/Pharma News
|
Posted 17/01/2014
0
Post your comment

The pharmaceutical industry has been pressing the Pakistan Government for an increase in drug prices in line with increased production costs. Drugmakers argue that the dispute is not only creating the medicines shortage, but is also discouraging future investment in the industry. The industry argues that Pakistani companies cannot export their products to industrialized countries because of the lack of international certifications and for that, they need major investment, which is difficult to make in present conditions.
Drugmakers have accused the Pakistan Government of dragging the pricing issue out for a long time and are warning that if the situation is not resolved soon the medicines shortage situation could get worse.
Pakistan’s drug manufacturers are seeking an increase of at least 18% in prices of all registered drugs whereas the government is said to have agreed to a 15% increase, with the government insisting that it has to consider both the interests of consumers and the concerns of investors.
Perhaps even more worrying is the fact that the situation is said to be providing an opportunity for counterfeit drugs to enter the market because of ‘a phenomenal rise in the demand for major drugs’.
Related articles
Pakistani immigrants may confuse generics with counterfeit drugs
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Source: The Express Tribune
Guidelines
Advances in EMA plans to streamline biosimilar assessment
FDA issues guidance on AI use in drug and biologicals regulatory decision making
Policies & Legislation
ANVISA and Danish Medicines Agency renew health regulatory collaboration
Colombia and Brazil introduce reforms to enhance healthcare regulation
Colombia boosts health sovereignty through public-private biotech collaboration agreement

Home/Pharma News Posted 07/04/2025
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment